Randomized Trial and Pharmacokinetic Study of Pegfilgrastim versus Filgrastim after Dose-Intensive Chemotherapy in Young Adults and Children with Sarcomas
暂无分享,去创建一个
S. Steinberg | D. Hawkins | L. Helman | F. Balis | B. Widemann | C. Mackall | R. Dagher | N. Jayaprakash | E. Fox | A. Aikin | D. Bernstein | L. Long
[1] G. Lyman,et al. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials , 2007, Current medical research and opinion.
[2] N. Bhana,et al. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review , 2007, Current opinion in oncology.
[3] N. André,et al. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy , 2007, Anti-cancer drugs.
[4] Gisela Schwab,et al. Pharmacokinetic/Pharmacodynamic Modeling of Pegfilgrastim in Healthy Subjects , 2006, Journal of clinical pharmacology.
[5] Thomas J. Smith,et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] I. Bruns,et al. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma , 2006, Transfusion.
[7] W. Kamps,et al. Pegfilgrastim in Pediatric Cancer Patients , 2005, Journal of pediatric hematology/oncology.
[8] C. Urban,et al. Once-Per-Cycle Pegfilgrastim Versus Daily Filgrastim in Pediatric Patients With Ewing Sarcoma , 2005, Journal of pediatric hematology/oncology.
[9] B. Wiens,et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Nathan,et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] N. Jaffe,et al. Safety and efficacy of pegfilgrastim in pediatric oncology patients: The M.D. Anderson Cancer Center experience. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Roskos,et al. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. , 2004, Journal of pharmaceutical sciences.
[13] G. Molineux. The design and development of pegfilgrastim (PEG-rmetHuG-CSF, Neulasta). , 2004, Current pharmaceutical design.
[14] William C Zamboni,et al. Pharmacokinetics of Pegfilgrastim , 2003, Pharmacotherapy.
[15] W. Leslie,et al. Selective Cyclooxygenase‐2 Inhibition: A Target in Cancer Prevention and Treatment , 2003, Pharmacotherapy.
[16] M. Piccart,et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[17] J. Crawford. Neutrophil growth factors. , 2002, Current hematology reports.
[18] L. R. Hill,et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] J. Crawford,et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Shaun Parsons,et al. Growth factor practice patterns among pediatric oncologists: results of a 1998 Pediatric Oncology Group Survey. Economic Evaluation Working Group the Pediatric Oncology Group. , 2000, Journal of pediatric hematology/oncology.
[21] S. Steinberg,et al. Ifosfamide and etoposide plus vincristine, doxorubicin, and cyclophosphamide for newly diagnosed Ewing's sarcoma family of tumors , 1996, Cancer.
[22] V. Dilsizian,et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.